Are you at the Global Industrie exhibition in Paris Villepinte? Check out our partners in Hall 5, booth 5X92 #GI26 #GlobalIndustrie #GIAvenir #manufacturing #aerospace #circulargeometry #coordinatemeasuringmachines #metrology
Adding elraglusib, a novel small-molecule inhibitor, to chemotherapy significantly increases OS in patients with previously untreated metastatic #PDAC. Presented at @ascocancer.bsky.social conference #GI26.
https://bit.ly/3ZFQztG
#pancsm
For patients with treatment-naïve, unresectable #hepatocellularCarcinoma, nivolumab plus ipilimumab provides a sustained benefit compared to lenvatinib or sorafenib. Presented at @ascopost.bsky.social conference #GI26.
https://bit.ly/3LOSXeD
#HCC
CapOx does not offer a PFS advantage over CapCar, nor over nanoliposomal irinotecan, leucovorin and fluorouracil, in previously untreated, metastatic or unresectable #gastroesophagealAdenocarcinoma. Presented at @ascocancer.bsky.social conference #GI26.
https://bit.ly/3LYilhR
#GEA #gicsm
Anytime we can join @chadinabhan.bsky.social for
a special #HealthcareUnfiltered episode, we're all in. I was pleased to join @shaalanbeg.bsky.social & @shrutipatelmd.bsky.social to highlight data from @ascocancer.bsky.social #GI26
Listen or watch the #podcast:
podcasts.apple.com/us/podcast/e...
The incidence of #colorectalcancer among users of GLP-1RAs was approximately 36% lower than that observed among aspirin users. Presented at @ascocancer.bsky.social #GI26, covered by @cancertherapyadv.bsky.social.
https://bit.ly/3Z7ToUj
#GLP1 #crcsm
Online patient and caregiver conversations focused on neuroendocrine neoplasms (NENs): A global thematic analysis was published at #GI26 #ASCOGI
ascopubs.org/doi/10.1200/...
Loved collaborating with @ugrewalmd.bsky.social on this one
The use of GLP-1 receptor antagonist therapy has led to a greater reduction in #colorectalcancer incidence than has been observed with aspirin. Presented at #GI26.
https://bit.ly/45jGd6a
#crcsm #GLP1RA
News - ASCO Gastrointestinal Cancers Symposium 2026
www.thelancet.com/journals/lan...
#GI26 #ASCOGI #GastroSky #OncSky #MedSky
If you haven’t yet watched the #GI26 Keynote by Dr. W. Kimryn Rathmell, “Meeting Patients With Cancer Where They Are—The Role of Dyad Partnerships in Oncology,” it’s now available to all: brnw.ch/21wZ9GS
Zanidatamab Plus Chemo With/Without Tislelizumab Yields Unprecedented PFS/OS Outcomes in HER2+ Gastroesophageal Adenocarcinoma
Lead author Elena Elimova, MD, details the implications of findings from HERIZON-GEA-01 trial shared at ASCO #GI26 www.onclive.com/view/zanidat...
Take a look behind the scenes of the 2026 Gastrointestinal Cancers Symposium! Intrigued by the expert insights? Check out our coverage for more exclusive #GI26 highlights! @ascocancer.bsky.social #oncology
www.onclive.com/conference/gi
ICYMI at #GI26: 2 novel KRAS-targeted treatments demonstrated manageable safety profiles and promising efficacy in early-phase studies of patients w/ PDAC and KRAS G12D mutations.
#ASCODailyNews has more: brnw.ch/21wZ79x
Stay up to date with expert insights from #GI26! 🌍
👉 buff.ly/9zzT5L3
The 2026 ASCO Gastrointestinal Cancer Congress brings together global leaders in GI oncology to share the latest advances—from molecular discoveries and targeted therapies to immunotherapy, surgery, and supportive care.
Compared to standard care, zanidatamab plus chemotherapy delays progression or death in patients with untreated locally advanced or metastatic gastroesophageal adenocarcinoma. Presented at #GI26 by Elena Elimova, MD of @pmresearch-uhn.bsky.social.
https://bit.ly/4qniKJU
#GEA #gicsm
Encorafenib/Cetuximab Plus FOLFIRI Represents Potential New Frontline SOC in BRAF V600E+ mCRC @skopetz.bsky.social @mdanderson.bsky.social @ascocancer.bsky.social #GI26 #oncology #crcsm www.onclive.com/view/encoraf...
Penpulimab-Based Quadruplet Yields Efficacy Improvements in Metastatic Pancreatic Cancer
#pancsm #oncology #GI26
www.onclive.com/view/penpuli...
Back to clinic today where we are wearing masks throughout the hospital. Opportunity to mention benefits of physical activity for early stage treated colorectal cancer to reduce fatigue and improve QoL based on what was learned at #GI26 @ASCO on Saturday in San Francisco.
The response rate in metastatic gastroesophageal cancer improved by a relative 50% when patients received experimental activated T cells in addition to standard therapy, according to a small phase II study. #GI26
www.medpagetoday.com/meetingcover...
Patients with colorectal cancer had significantly less fatigue and better quality of life when they remained physically active during treatment and recovery, a large prospective study showed. #GI26
www.medpagetoday.com/meetingcover...
An immuno-oncology regimen for intermediate-stage hepatocellular carcinoma significantly extended treatment benefit versus transarterial chemoembolization, according to an interim analysis of a randomized trial. #GI26
www.medpagetoday.com/meetingcover...
Almost 80% of patients with heavily pretreated advanced/metastatic pancreatic cancer achieved disease control with a novel KRAS G12D inhibitor, a small preliminary study showed. #GI26
www.medpagetoday.com/meetingcover...
Missed #GI26? Read our coverage of @ascocancer.bsky.social ⬇️
Now that #GI26 is over, catch up on all the news from the meeting with #ASCODailyNews. All coverage of the Symposium's top research can be found here: brnw.ch/21wZ1z3
🔗 Read more: bit.ly/ONCOnews12J-06
#ONCOnews #OncoAlert #OncEd #ColorectalCancer #CancerResearch #ASCO #GI26
🔗 Read more: bit.ly/ONCOnews12J-05
#ONCOnews #OncoAlert #OncEd #ColorectalCancer #CancerRecovery #HealthyLifestyle #QualityOfLife #ASCO #GI26
NOW OUT‼️ The #GI26 COMPLETE🚨Newsletter
REGISTER TO GET IT at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
OUR PICKS of The TOP Trials from #GI26 SAN FRANCISCO🇺🇸
ALL IN ONE PLACE!!
✅ HERIZON-GEA-01
✅ILUSTRO
✅LUCERNA
✅CRITICS II
✅NEOSUMMIT-01
✅STOPGAP II
✅LyRICX
✅Keynote 937
any more
🔗 Read more: bit.ly/ONCOnews12J-04
#ONCOnews #OncoAlert #OncEd #PancreaticCancer #Oncology #PrecisionMedicine #ASCO #GI26
